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The low molecular weight heparins (LMWHs) represent a
group of antithrombotic and anticoagulant drugs which
were initially developed for the prophylaxis of surgical
thrombosis some 20 years ago. Today these drugs are used
in expanded indication including venous thrombosis, car-
diovascular disorders, thrombotic and ischemic strokes,
cancer and neurodegenerative diseases. Because of the
polytherapeutic actions these drugs can be differentiated
from other older and newer antithrombotic drugs as
stated in the following.
1. Differentiation of low molecular weight heparins from
unfractionated heparins
2. Differentiation of commercially available low molecu-
lar weight heparins, which are produced by different
methods.
3. Differentiation of the branded low molecular weight
heparins from the generic versions of these drugs.
4. Differentiation of low molecular weight heparins from
synthetic heparin derived oligosaccharides such as the
pentasaccharides such as Arixtra and Idraparinux.
5. Differentiation of low molecular weight heparins from
heparinoids and GAG mixtures such as the danaparoid,
dermatan and heparans.
6. Differentiation of low molecular weight heparins from
synthetic anti-Xa agents.
7. Differentiation of low molecular weight heparins from
synthetic anti-IIa agents
8. Differentiation of low molecular weight heparins from
oral anticoagulant drugs such as warfarin.
It is now clear that the clinical spectrum of the LMWHs is
relatively broader from the different anticoagulant/anti-
thrombotic drugs. Moreover, these agents have multiple
interactions with plasmatic and cellular components and
produce polytherapeutic effects. The synthetic mono-
therapeutic agents therefore will not have the same broad
clinical profile as the LMWHs. It is important to differen-
tiate the therapeutic effects of individual LMWH as each of
these products is approved for specific indications. More
recently dalteparin is approved for the treatment of can-
cer-associated thrombosis, an indication, which is solely
approved for this product for this time. Therefore, it is
important to differentiate these drugs and caution should
be exercised for therapeutic and generic interchange.
Of all anticoagulants developed during the past 25 years,
LMWHs have become the standard of care for the manage-
ment of venous thromboembolism. Unlike unfraction-
ated heparin (UFH), different brands of LMWHs can be
differentiated biologically and clinically. Based on their
different pharmacological and therapeutic profiles,
LMWHs are largely considered by the experts and regula-
tory agencies such as the US FDA to be distinct drugs
requiring indication and dosage specifications for each
product. Therapeutic and generic interchanges are not rec-
ommended among different LMWHs, as this may com-
promise medical and surgical patient care [1]. The
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differences among the LMWHs are due to their molecular
and structural properties.
LMWHs are a biological product derived from UFH
obtained from animal tissue. In this regard, heparins are
not drugs with one simple chemical structure, such as
aspirin and statins. Heparins are a complex mixture of het-
erogeneous sugar chains. To produce LMWHs, the long
chains of UFH are cleaved by different procedures so that
the average molecular weight of the resulting heparin is of
a lower molecular weight.
Beyond the average molecular weight, however, LMWHs
can be further characterized [2-5]. Depending on the deg-
radation processes (chemical β elimination [enoxaparin],
enzymatic β elimination [tinzaparin], nitrous acid depo-
lymerization [dalteparin], oxidative cleavage [ardeparin])
different compounds are generated. If the individual
heparin chains that can contain 2–40 sugar units are iden-
tified, different proportions are present within each
LMWH. Chemical modifications are also made to the sac-
charide chains, either at the cleavage endpoint or within
the chain. Specific structural attributes that may or may
not be induced by each degradation process include
microchemical changes (e.g., addition or deletion of sul-
fate and acetyl groups), charge density, double-bond for-
mation, formation of anhydro-manno or anhyro-gluco
groupings, and the presence of 5-membered rings. For
enoxaparin, approximately 30% of its molecules cannot
be characterized by direct analysis. Thus, there are likely to
be additional structural differences that would cause dif-
ferentiation among LMWHs.
Due to the average molecular-weight difference of
LMWHs from UFH, LMWHs generally have a lesser ability
to inhibit thrombin (anti-FIIa activity), increased bioa-
vailability, and decreased clearance rate. However, the
specific chemical or structural features of each LMWH fur-
ther translate into individualized biological and pharma-
cological characteristics of each LMWH. The chemical
features contribute to differential binding affinities to
antithrombin, von Willebrand's factor, growth factors,
and other plasma proteins, interactions with platelets,
leucocytes, vascular endothelial cells (release of tissue fac-
tor protein inhibitor is one example), and other biological
components. Thus, beside the anticoagulant action, anti-
thrombotic, anti-inflammatory, antiproliferative, and
immunological actions are affected by the structural
attributes of a LMWH. Only 20% of the components of
heparins are anticoagulant in nature. The other 80%
exhibit multiple biological actions that contribute to the
overall effects of LMWHs, although this is not yet fully
understood.
These variable biological interactions are reflected in dif-
fering pharmacological characteristics, including absorp-
tion, elimination half-life, and renal clearance [2-5]. Both
the biological and pharmacological differences impact on
the clinical safety and efficacy of each LMWH. The clinical
performance of enoxaparin, dalteparin, and nadroparin
has been differentiated in various settings [1,6]. Levels of
evidence also exist relating to the variable effects of differ-
ent LMWHs on specific patient populations, e.g., patients
with renal impairment. These clinical differences among
LMWHs would be more obvious with the higher dosages
and extended treatment modalities that are being devel-
oped.
Therefore, LMWHs are complex biological drug products
of comparable molecular weight, but with individual bio-
logical, pharmacological, and clinical characteristics.
Potency adjustments of these complex drugs, based solely
on anti-FXa and anti-FIIa do not minimize the variations
between the LMWHs. Similarly, new antithrombotic
agents [7,8] should be differentiated from the LMWHs on
the basis of product quality, mechanism of drug anti-
thrombotic activity, pharmacological behavior, and clini-
cal safety and efficacy.
The LMWHs can also be differentiated from oral anticoag-
ulant drugs such as warfarin. More importantly, being a
small molecule warfarin is capable of passing the placen-
tal barriers and can not be used in pregnancy. While defin-
itive clinical trials validating the use of LMWHs in
pregnancy are not available at this time, this is one indica-
tion where these drugs may be very useful. The newly
developed anti-IIa drugs such as dabigatran and anti-Xa
drugs such as epixiban are also capable of passing the pla-
cental barrier and therefore cannot be used in this indica-
tion. Furthermore, all of these drugs are small molecular
weight peptidomimetics which may exhibit some hemo-
dynamic effects and modulation of hepatic enzymes. As
such, the anti-IIa and anti-Xa drugs are also not the same
and can be differentiated within their own group.
Venous thrombosis regardless of its origin is a complex
pathophysiologic process. While tissue factor, coagulation
proteases and their inhibitors contribute to the overall
pathogenesis of thrombosis several additional factors play
an important role in the overall clinical picture of this syn-
drome. Thus, single target drugs are of limited value for
the overall management of VTE. Moreover the toxicity of
these agents is not understood at this time. Therefore, one
should be cautious in recommending these drugs as
potential replacement for LMWH and oral anticoagulant
drugs.
In summary, despite the development of several newer
mono-therapeutic agents such as the anti-FXa, anti-FIIa,Publish with BioMed Central    and   every 
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and recombinant protein inhibitors, the LMWHs remain
the standard of care for venous thromboembolism man-
agement. Thrombosis is a polypathologic syndrome and
can be best managed by poly-therapeutic drugs such as
LMWHs. Because of the structural and functional differ-
ences among the currently available LMWHs the thera-
peutic interchange of these drugs is not recommended [9].
Moreover, because of the lack of proper guidelines for the
acceptance of the generic versions of LMWHs the generic
interchange is not recommended until proper guidelines
and biologic equivalence is established.
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